Related Experiment Video
Updated: Jun 2, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Infantile haemangioma and β-blockers in otolaryngology
N Leboulanger1, A Cox, E-N Garabedian
1Service d'ORL et de chirurgie cervicofaciales pédiatriques, centre de références des malformations ORL rares, hôpital d'enfants Armand-Trousseau, AP-HP, université Paris VI-Pierre-et-Marie-Curie, 26, avenue du Dr-Arnold-Netter, 75012 Paris, France. nicolas.leboulanger@trs.aphp.fr
Abstract:
Infantile haemangioma (IH) is the most common tumour during early childhood. Although these benign lesions resolve spontaneously, up until recently laryngotracheal sites of IH required invasive management. The dramatic efficacy of β-blockers on IH has radically changed the prognosis. Surgery is now no longer indicated as first-line therapy, but should only be performed for difficult, refractory cases, or in the presence of absolute contraindications to β-blockers. Long-term steroid therapy is also no longer indicated. Propranolol can be used as first-line, single-agent therapy.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Heart Failure Drugs: β-Blockers
